MALVERN, Pa., July 29, 2026
Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OCU410, the company’s investigational AAV5-based gene therapy, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The designation is intended to expedite the development and regulatory review of regenerative medicines addressing serious conditions with significant unmet medical needs. The FDA’s decision was supported by positive Phase 2 clinical data demonstrating clinically meaningful efficacy and a favorable safety profile, with no treatment-related serious adverse events reported. The RMAT designation strengthens Ocugen’s strategy of developing a one-time gene therapy designed to provide long-term benefit, differentiating OCU410 from currently approved therapies that require repeated intravitreal injections.
Phase 2 Data Supports Accelerated Regulatory Development
The RMAT designation recognizes preliminary clinical evidence indicating that OCU410 has the potential to address a serious disease with limited treatment options. Geographic atrophy is an advanced form of dry age-related macular degeneration, leading to progressive and irreversible central vision loss. According to Ocugen, an estimated 2 to 3 million people across the United States and Europe are affected by GA, while dry AMD impacts nearly 10 million Americans and more than 266 million people worldwide. The company stated that OCU410 targets multiple biological pathways involved in retinal degeneration, including oxidative stress, inflammation, complement regulation, and lipid metabolism, through delivery of the RORA (retinoid-related orphan receptor alpha) gene. This gene-agnostic approach aims to restore retinal balance and potentially provide a durable therapeutic benefit following a single subretinal administration.
Phase 3 Trial Planned Following FDA Alignment
Earlier in July 2026, Ocugen reached agreement with the FDA on the design of its Phase 3 registrational clinical trial for OCU410. The company expects to initiate the Phase 3 study during the third quarter of 2026, with a planned Biologics License Application (BLA) submission in 2028. The RMAT designation provides important regulatory advantages, including enhanced FDA interactions, eligibility for rolling BLA review, and potential access to Priority Review and Accelerated Approval, where applicable. These benefits are intended to streamline the clinical development process while supporting earlier patient access if the therapy ultimately demonstrates safety and efficacy in late-stage studies.
Advertisement
One-Time Gene Therapy Aims to Address Major Unmet Need
OCU410 is being developed as a one-time gene therapy for patients with geographic atrophy secondary to dry AMD, offering a potential alternative to chronic treatment approaches. The investigational therapy has also received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency, further supporting its global development. Ocugen continues to advance its modifier gene therapy platform, which is designed to treat retinal diseases by targeting the underlying biology rather than individual gene mutations. In addition to geographic atrophy, the company is developing gene therapies for retinitis pigmentosa and Stargardt disease, reinforcing its focus on innovative treatments for inherited and age-related blindness.
Source: Ocugen, press release
